Towards Healthcare
Chronic Obstructive Pulmonary Disease (COPD) Market Size | CAGR - 4.42% by 2033

Chronic Obstructive Pulmonary Disease (COPD) Market Size (USD 33.29 Bn) by 2033

The report covers Chronic Obstructive Pulmonary Disease (COPD) Market Trends and Segments classified by disease type covering emphysema and chronic bronchitis. The treatment type categorized into drugs and surgery, with drugs divided into bronchodilator monotherapy (including short-acting beta2-agonists (SABAs) and long-acting beta2-agonists (LABAs)) and anti-inflammatory drugs (including oral and inhaled corticosteroids and anti-leukotrienes). Surgical treatments include lung volume reduction surgery (LVRS), lung transplant, bullectomy and others. The end user type highlights hospitals and clinics, homecare settings and other relevant healthcare environments. The report offers the value (in USD Billion) for the above segments.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific 
      • China
      • Japan
      • India
      • South Korea
      • Rest of Asia-Pacific
    • Rest of the World

North America Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • U.S.
    • Canada

Europe Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe

Asia-Pacific Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific

Rest of the World Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others

Company Profiles

  • Almirall
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Abbott Laboratories
  • Dr. Reddy’s Laboratories Ltd.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Pfizer Inc.
  • Astellas Pharma
  • Novartis AG
  • Merck & Co., Inc.

Conclusion & Recommendations

  • Insight Code: 5154
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a dedicated market research professional with over 2 years of experience in the healthcare industry. Specializing in healthcare market research, she brings valuable expertise in analyzing market trends, evaluating industry dynamics, and providing actionable insights to help businesses stay ahead in a competitive market.

Throughout her career, Deepa has focused on delivering in-depth research on various healthcare segments, including pharmaceuticals, biotechnology, and healthcare services. She excels in identifying emerging opportunities, assessing market risks, and understanding regulatory changes that impact the healthcare sector.

Her ability to synthesize complex data and translate it into clear, concise recommendations makes her a key contributor to successful strategic decision-making. Her work helps organizations better understand consumer behavior, market demands, and the regulatory landscape, facilitating informed business strategies.

With a passion for healthcare research and a commitment to excellence, Deepa continues to provide businesses with the market intelligence they need to thrive in an increasingly complex healthcare environment. Her insights are critical for companies seeking to navigate the evolving healthcare landscape and optimize their market positioning.

FAQ's

Breathing becomes more difficult with COPD. At initially, the symptoms might be minor, starting with breathlessness and sporadic coughing. Breathing may become more challenging as the symptoms worsen and become more persistent.

There are several similarities between COPD and asthma, including symptoms such as breathing difficulties and airflow obstruction. However, COPD is a progressive, long-term condition. Allergens frequently trigger asthma attacks. Smoking is the major cause of COPD.

Healthcare practitioners will be using a collection of established clinical and biochemical indicators that predict therapy by 2030 to evaluate our patients.

ClinicalTrails.gov, World Health Organization, U.S. National Library of Medicine, Centers for Disease Control and Prevention, American Lung Association

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 515

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 515